DMAQ Stock Overview
Deep Medicine Acquisition Corp. does not have significant operations.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Deep Medicine Acquisition Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.96 |
| 52 Week High | US$19.91 |
| 52 Week Low | US$2.96 |
| Beta | 0.017 |
| 1 Month Change | -74.59% |
| 3 Month Change | -74.59% |
| 1 Year Change | -71.12% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -69.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| DMAQ | US Capital Markets | US Market | |
|---|---|---|---|
| 7D | -68.4% | 2.5% | 1.7% |
| 1Y | -71.1% | 38.7% | 26.3% |
Return vs Industry: DMAQ underperformed the US Capital Markets industry which returned 9.7% over the past year.
Return vs Market: DMAQ underperformed the US Market which returned 18% over the past year.
Price Volatility
| DMAQ volatility | |
|---|---|
| DMAQ Average Weekly Movement | 26.6% |
| Capital Markets Industry Average Movement | 3.3% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: DMAQ's share price has been volatile over the past 3 months.
Volatility Over Time: DMAQ's weekly volatility has increased from 13% to 27% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | n/a | Humphrey Polanen | n/a |
Deep Medicine Acquisition Corp. does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It focuses on identifying businesses in the healthcare industry.
Deep Medicine Acquisition Corp. Fundamentals Summary
| DMAQ fundamental statistics | |
|---|---|
| Market cap | US$36.56m |
| Earnings (TTM) | -US$612.16k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-21.1x
P/E RatioIs DMAQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DMAQ income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$612.16k |
| Earnings | -US$612.16k |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.14 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -29.2% |
How did DMAQ perform over the long term?
See historical performance and comparison